Japan's Eisai opens $100 million parenteral facility in Research Triangle Park, USA

The US subsidiary of Japanese drug major Eisai commemorated the opening of its newly constructed parenteral facility in Research Triangle Park (RTP), North Carolina. The new site will be utilized for the commercial production and formulation R&D of intravenous treatments.

The 65,000-square-foot facility will serve as Eisai's global commercial manufacturing and drug development site for intravenous drug products in support of the company's global clinical development programs, including those for oncology. Eisai invested approximately $100 million in the new facility, which encompasses aseptic processing suites, laboratories and other support functions. The new operation is designed to handle and process highly potent compounds utilizing state-of-the-art isolator containment technology.